1. Home
  2. SNAL vs NOTV Comparison

SNAL vs NOTV Comparison

Compare SNAL & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Snail Inc.

SNAL

Snail Inc.

N/A

Current Price

$0.54

Market Cap

29.8M

Sector

Technology

ML Signal

N/A

Logo Inotiv Inc.

NOTV

Inotiv Inc.

HOLD

Current Price

$0.27

Market Cap

10.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNAL
NOTV
Founded
2000
1974
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.8M
10.8M
IPO Year
2022
1997

Fundamental Metrics

Financial Performance
Metric
SNAL
NOTV
Price
$0.54
$0.27
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
20.2K
416.6K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
120.00
49.64
EPS
N/A
N/A
Revenue
$81,225,622.00
$547,656,000.00
Revenue This Year
$49.44
$5.28
Revenue Next Year
N/A
$5.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
511.19
52 Week Low
$0.50
$0.24
52 Week High
$2.15
$3.31

Technical Indicators

Market Signals
Indicator
SNAL
NOTV
Relative Strength Index (RSI) 30.69 38.82
Support Level N/A $0.26
Resistance Level $0.98 $0.46
Average True Range (ATR) 0.05 0.04
MACD -0.01 -0.01
Stochastic Oscillator 6.39 12.30

Price Performance

Historical Comparison
SNAL
NOTV

About SNAL Snail Inc.

Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

Share on Social Networks: